CPHI

China Pharma Holdings, Inc. (CPHI) | Rumor.io

China Pharma Holdings

CPHI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,249

Bullish sentiment (50-day avg)86%

Price to earnings ratio-0.89

Market capitalization31M

Earnings per share-0.42

Dividend yield (TTM)—

Revenue (annual)4.1M

Net income (annual)-3.2M

Social

What share of all stock conversation is about CPHI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Sep 25

China Pharma Holdings, Inc. (CPHI) is mentioned as a potential big runner, with some users predicting a significant price increase.
CPHI is compared to other Chinese stocks, such as MSGY, INLF, and TDIC, which have previously seen significant price increases.
Users are speculating that CPHI could reach $1 or even $2, citing a strong China theme and potential for a squeeze.

Generated by AI

Sentiment

Of the messages about CPHI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67%	90.32% -9.68	91.04% +13.54	80.9% -3.59
Bearish	33.33%	9.68% +9.68	8.96% -13.54	19.1% +3.59

Bullish· Sep 25

$CPHI has the potential to hit $19, and could even reach $50, given its previous performance and the current China theme.
The company's previous run, where it saw a 200% gain, could be a repeat scenario, with the stock potentially breaking out to new highs.
$CPHI's strong China theme and increasing momentum make it a potential candidate for a parabolic run, with the stock gaining traction and possibly hitting $1 or higher.

Bearish· Jul 22

The stock has been manipulated by the Chinese mafia, making it a risky investment opportunity.
China Pharma Holdings' valuation is extremely high, with a beta of 0.97 and a 2020% range, making it a potentially volatile asset.
The company's recent price drop is a sign of a larger issue, with some traders comparing it to the Chinese stocks' tendency to be pump and dump schemes.

Generated by AI

Topics

Of the messages about CPHI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	5.26%	34.83%
Technical Analysis	—	0%	57.89%	27.99%
Macro	—	0%	36.84%	36.32%
Analysts	—	0%	0%	0.87%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%

Announcements· Jan 7

China Pharma Holdings, Inc. has filed a prospectus supplement with the U.S. SEC to offer and sell up to $600,000 of common stock.
The company has successfully completed all redemptions under its Convertible Promissory Note agreement with Streeterville Capital, LLC as of December 11, 2024.
This marks a significant step in strengthening China Pharma's financial position and reflects its commitment to sound fiscal management.

Technical Analysis· Jul 21

$CPHI has shown strength in reclaiming levels, invalidating the liquidation thesis, and may signal that the liquidation pressure is fading.
A sustained move through $8.40-$8.50 could be a healthier confirmation of buying pressure, setting up another test of $9.20, and may indicate a bigger momentum move.
$CPHI has delivered a move of more than 200% from the original mention around $3.00, with a strong focus on the $10.00 psychological resistance, and may open the door for further momentum if cleared.

Generated by AI

Community

Of the messages about CPHI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	60.38%	62.5%	29.66%
Newcomers	0%	39.62%	37.5%	70.34%

Regulars· Sep 25

The company's stock price is expected to break through $0.80, setting up a potential breakout and hitting scanners already.
Regulars believe the stock has the ingredients to squeeze, similar to last time when it ran over 200%, and could see significant gains.
The stock is gaining momentum on the China theme, which is strong, and could see a parabolic increase, similar to last time when it saw 200% gains.

Newcomers· Aug 13

The newcomer is focused on the stock's recent price movement, noting that it pumped up to $1.50 and then collapsed back to $1.20, warning of a potential micro-cap distribution pattern.
The newcomer is concerned about the stock's volatility, citing a 52-week range of $0.38 to $19.19 and a history of brutal dilution and bag-holder creation, advising against turning a day trade into a long-term investment.
The newcomer is unsure about the reason behind the stock's overnight climb, asking what the news is, and is also aware of the stock's potential for sudden drops, joking about a typical scenario for a Chinese stock.

Generated by AI

News

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

6d agoReuters

European drugmakers call for faster trials, more spending to compete with US, China

7d agoReuters

Pharmaceutical Companies Push Trump Administration to Protect China Deals

8d agoWSJ

U.S. weighs allowing most pharma licensing deals with China

The U.S. is drafting rules for biopharma firms investing in China that would likely maintain their ability to ink most licensing deals for Chinese drugs. Read more here.

12d agoSeeking Alpha

EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say

12d agoReuters

The West is hooked on Chinese drugs but they could save your life

13d agoThe Telegraph

Also Discussed

Investors talking about CPHI also mention

#	Name	Attention
1	China SXT Pharmaceuticals, Inc.SXTC	0%0
2	ZW Data Action Technologies Inc.CNET	0%0
3	My Size, Inc.MYSZ	0%new
4	Zhongchao Inc. Class A Ordinary SharesZCMD	0%new
5	InspireMD, Inc.NSPR	0%new
6	TTNP - Titan Pharmaceuticals, Inc.	——
7	Co-Diagnostics Inc.CODX	0%+0
8	BIMI - BIMI International Medical Inc.	——
9	Taoping Inc.TAOP	0%0
10	CREG - Smart Powerr Corp.	——

China Pharma Holdings, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

China Pharma Holdings, Inc. is a specialty pharmaceutical company focused on the development, manufacture, and marketing of human-use medicines in China. Its current portfolio covers products for central nervous system and cerebral-cardiovascular disorders, anti-infection and respiratory conditions, digestive diseases, comprehensive healthcare, and protective products. The company offers pharmaceuticals in multiple dosage forms, including injectables, tablets, capsules, and oral solutions, serving hospitals and private retailers across its domestic market. China Pharma Holdings, Inc. operates as a vertically integrated drug manufacturer, combining research, production, and commercialization within its business model. Based in Haikou, China, the company plays a role in supplying medicines for widely prevalent medical conditions in the Chinese healthcare market.

Website

Location

No. 17, Jinpan Road

Haikou, 570216

China

Social

What share of all stock conversation is about CPHI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Sep 25

China Pharma Holdings, Inc. (CPHI) is mentioned as a potential big runner, with some users predicting a significant price increase.
CPHI is compared to other Chinese stocks, such as MSGY, INLF, and TDIC, which have previously seen significant price increases.
Users are speculating that CPHI could reach $1 or even $2, citing a strong China theme and potential for a squeeze.

Generated by AI

Sentiment

Of the messages about CPHI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67%	90.32% -9.68	91.04% +13.54	80.9% -3.59
Bearish	33.33%	9.68% +9.68	8.96% -13.54	19.1% +3.59

Bullish· Sep 25

$CPHI has the potential to hit $19, and could even reach $50, given its previous performance and the current China theme.
The company's previous run, where it saw a 200% gain, could be a repeat scenario, with the stock potentially breaking out to new highs.
$CPHI's strong China theme and increasing momentum make it a potential candidate for a parabolic run, with the stock gaining traction and possibly hitting $1 or higher.

Bearish· Jul 22

The stock has been manipulated by the Chinese mafia, making it a risky investment opportunity.
China Pharma Holdings' valuation is extremely high, with a beta of 0.97 and a 2020% range, making it a potentially volatile asset.
The company's recent price drop is a sign of a larger issue, with some traders comparing it to the Chinese stocks' tendency to be pump and dump schemes.

Generated by AI

Topics

Of the messages about CPHI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	5.26%	34.83%
Technical Analysis	—	0%	57.89%	27.99%
Macro	—	0%	36.84%	36.32%
Analysts	—	0%	0%	0.87%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%

Announcements· Jan 7

China Pharma Holdings, Inc. has filed a prospectus supplement with the U.S. SEC to offer and sell up to $600,000 of common stock.
The company has successfully completed all redemptions under its Convertible Promissory Note agreement with Streeterville Capital, LLC as of December 11, 2024.
This marks a significant step in strengthening China Pharma's financial position and reflects its commitment to sound fiscal management.

Technical Analysis· Jul 21

$CPHI has shown strength in reclaiming levels, invalidating the liquidation thesis, and may signal that the liquidation pressure is fading.
A sustained move through $8.40-$8.50 could be a healthier confirmation of buying pressure, setting up another test of $9.20, and may indicate a bigger momentum move.
$CPHI has delivered a move of more than 200% from the original mention around $3.00, with a strong focus on the $10.00 psychological resistance, and may open the door for further momentum if cleared.

Generated by AI

Community

Of the messages about CPHI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	60.38%	62.5%	29.66%
Newcomers	0%	39.62%	37.5%	70.34%

Regulars· Sep 25

The company's stock price is expected to break through $0.80, setting up a potential breakout and hitting scanners already.
Regulars believe the stock has the ingredients to squeeze, similar to last time when it ran over 200%, and could see significant gains.
The stock is gaining momentum on the China theme, which is strong, and could see a parabolic increase, similar to last time when it saw 200% gains.

Newcomers· Aug 13

The newcomer is focused on the stock's recent price movement, noting that it pumped up to $1.50 and then collapsed back to $1.20, warning of a potential micro-cap distribution pattern.
The newcomer is concerned about the stock's volatility, citing a 52-week range of $0.38 to $19.19 and a history of brutal dilution and bag-holder creation, advising against turning a day trade into a long-term investment.
The newcomer is unsure about the reason behind the stock's overnight climb, asking what the news is, and is also aware of the stock's potential for sudden drops, joking about a typical scenario for a Chinese stock.

Generated by AI

China Pharma Holdings

Social

Sep 25

Bullish· Sep 25

Bearish· Jul 22

Announcements· Jan 7

Technical Analysis· Jul 21

Regulars· Sep 25

Newcomers· Aug 13

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

European drugmakers call for faster trials, more spending to compete with US, China

Pharmaceutical Companies Push Trump Administration to Protect China Deals

U.S. weighs allowing most pharma licensing deals with China

EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say

The West is hooked on Chinese drugs but they could save your life

Also Discussed

China Pharma Holdings, Inc.

Company Information

Location

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

European drugmakers call for faster trials, more spending to compete with US, China

Pharmaceutical Companies Push Trump Administration to Protect China Deals

U.S. weighs allowing most pharma licensing deals with China

EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say

The West is hooked on Chinese drugs but they could save your life

Also Discussed

Social

Sep 25

Bullish· Sep 25

Bearish· Jul 22

Announcements· Jan 7

Technical Analysis· Jul 21

Regulars· Sep 25

Newcomers· Aug 13